Effect of Fibroblast-Derived Interferon Administration on Immune Responsiveness in a Patient with Nasopharyngeal Carcinoma

Matheson, David S.; Tan, Y. H.; Green, Bridget; Mcpherson, T. A.

doi:10.1089/jir.1983.3.437

Cited by 4 publications

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx

Mahjoubi¹,

Bachouchi²,

Munck³

et al. 1993

Head & Neck

View full text Add to dashboard Cite

The presence of Epstein-Barr virus (EBV) genomes in the DNA of tumor cells of undifferentiated carcinoma of nasopharyngeal type (UCNT), associated with significant lymphocytic infiltration of tumor led to therapeutic trials with interferon (IFN) because of its antiviral, antiproliferative, and immunomodulatory properties. Fourteen patients with histologically proven UCNT (2 had locoregional disease alone and 12 metastatic disease) who were refractory to conventional chemotherapy, were treated with IFN gamma 20 x 10(6) U twice a week. Treatment was well tolerated. No objective response were achieved in the 13 evaluated patients, and all patients progressed after a median treatment duration of 10 weeks (6-32). IFN gamma seems unable to induce antitumor activity alone in such heavily pretreated patients. Its possible place in the management of UCNT is probably earlier in the natural history of this disease.

show abstract

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx

Mahjoubi¹,

Bachouchi²,

Munck³

et al. 1993

Head & Neck

View full text Add to dashboard Cite

show abstract

Interferon‐β treatment of metastatic prostate cancer

Bulbul

Huben

Murphy

1986

Journal of Surgical Oncology

View full text Add to dashboard Cite

A limited clinical trial of Interferon-beta (Human Fibroblast Interferon) in the treatment of advanced, hormone-refractory prostate cancer was conducted by the National Prostate Cancer Project (NPCP Protocol 2100). Sixteen patients with metastatic prostate cancer who had failed prior hormone therapy were entered into the study. Treatment consisted of 6 X 10(6) units of Interferon-beta intravenously three times per week for 12 weeks. Chills and fever were seen in ten of the 16 patients (62.5%), and mild hematologic toxicity occurred in four patients. No complete or partial responses were observed. Three patients had stable disease by NPCP criteria for a mean duration of 6.3 months. Progression of disease was seen in 13 of the 16 patients, eight of whom progressed during therapy. The results of this study suggest that Interferon-beta has limited efficacy in the treatment of advanced, hormone-refractory prostate cancer.

show abstract

Nasopharyngeal carcinoma: relationship to Epstein-Barr virus and treatment with interferon

Connors¹,

Jacobs²

1987

Cancer Treatment and Research

View full text Add to dashboard Cite

Effect of Fibroblast-Derived Interferon Administration on Immune Responsiveness in a Patient with Nasopharyngeal Carcinoma

Cited by 4 publications

References 18 publications

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx

Phase II trial of recombinant interferon gamma in refractory undifferentiated carcinoma of the nasopharynx

Interferon‐β treatment of metastatic prostate cancer

Nasopharyngeal carcinoma: relationship to Epstein-Barr virus and treatment with interferon

Contact Info

Product

Resources

About